The 8th iteration of the ‘Impact of Biosimilar Competition in Europe’ report describes the effects on price, volume, and market share following the arrival of biosimilar competition in Europe. The report consists of observations on competitive markets, and a set of Key Performance Indicators (KPIs) to monitor the impact of biosimilars in 23 European markets. The report has been a long-standing source of information on the status of the biosimilars market.

Biologic medicines are an increasingly important component of pharmaceutical expenditure, due to their efficacy as treatments for complex conditions. Biologics represent 35% of medicine spending in Europe at list prices and are growing at a 11.3% compound annual growth rate (CAGR) over the past five years. This compares to a 6.3% CAGR for the total market. Biologics are increasingly important and have continued to grow faster than non-biologic medicines for over a decade. IQVIA’s 5 observations on the impact of biosimilar competition explore this and cover:

1. COVID-19: Biologic prescribing has rebounded, but macroeconomic challenges loom
2. Savings: The savings from biosimilar competition reach an all-time high
3. Access: Access is improving but a growing disparity is occurring across countries
4. Competition: Not all originators will see competition
5. Future: LOE will triple in the next 5 years versus the previous 5